MXCT
MaxCyte Inc
1.20$
-4.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.6% | +151.1% | +95.4% | -22.7% | +23.6% | +72.7% | +448.7% | +0.9% | -6.4% | -10.7% | -15.4% | |
| – | +2.7% | +154.9% | +93.5% | -26.5% | +8.9% | +85.1% | +497.6% | -6.7% | -24.6% | -9.7% | -31.1% | |
| – | -29.2% | +386.2% | +116.1% | -55.6% | +35.2% | +23.3% | +154.8% | -76.8% | +320.3% | -40.0% | -28.0% | |
| – | -29.2% | +386.2% | +116.1% | -43.0% | +15.7% | +108.1% | +633.7% | -10.9% | -26.0% | -8.2% | -33.3% | |
| – | +3.5% | +66.1% | +32.6% | +53.5% | -33.8% | +59.4% | +33.0% | +62.5% | -48.3% | -19.0% | -25.2% | |
| – | +15.4% | +22.9% | +0.9% | +66.5% | +65.1% | +16.6% | +20.6% | +64.9% | +42.5% | -27.1% | -15.3% | |
| – | – | – | – | +114.5% | +204.4% | +17.3% | +105.9% | +77.4% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +19.3% | +15.9% | +7.4% | +1.6% | +36.7% | +13.3% | +14.4% | +54.0% | +10.5% | -8.0% | -6.6% | |
| – | +19.0% | +11.0% | +28.1% | -9.2% | +42.2% | +24.3% | +34.5% | -1.2% | +15.7% | -11.6% | -9.6% | |
| – | -44.1% | -98.2% | +5,831.3% | +186.8% | -79.2% | +32.2% | -21.6% | -70.2% | +393.0% | +11.6% | +68.5% | |
| – | +64.4% | +40.7% | +36.4% | -4.8% | -49.3% | -57.4% | +104.5% | -84.0% | +154.5% | +82.8% | +3.2% | |
| – | – | – | – | +21.1% | -3.2% | +0.4% | – | – | – | – | – | |
| – | – | – | +285.5% | -37.3% | +10.7% | +144.3% | +691.3% | -3.4% | -8.6% | -11.2% | -16.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3,670.0% | -22.9% | +45.1% | +5.2% | +10.2% | +23.2% | +30.5% | +12.2% | +1.5% | +1.5% | +1.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.